Enterprise League logo
Gesynta Pharma AB Logo

Gesynta Pharma AB

UNVERIFIED COMPANY

You are in a "view as others" mode

Overview

Looks like Gesynta Pharma AB hasn't shared any information about their company.

Description

Gesynta Pharma's drug candidate GS-248 is in clinical phase II development for the treatment of endometriosis – a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life and current drug treatments are inadequate for many patients. Gesynta Pharma aims to exploit the full potential of microsomal prostaglandin E synthase-1 (mPGES-1) as a pharmacological target by developing products in areas of unmet medical need where mPGES-1 inhibition provides clear benefits compared to current therapy. The company's next drug candidate, GS-073, is ready to enter clinical phase I in 2023. Gesynta Pharma bases its R&D on research from the Karolinska Institutet. Major shareholders include Industrifonden, Hadean Ventures, Linc, and a number of successful life science entrepreneurs.

Founded 2017

10-20

Products

Looks like Gesynta Pharma AB has no published products yet.

Services

Looks like Gesynta Pharma AB has no published services yet.

Company reviews

This company reviews are private
Profile Strength:

undefined%

profile
completion

Add your telephone number
Contact details

info@gesynta.se

Stockholm, Sweden